La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
LifeTech Scientific Croissance future
Future contrôle des critères 4/6
LifeTech Scientific devrait augmenter ses bénéfices et son chiffre d'affaires de 20.5% et de 16.8% par an respectivement. Le BPA devrait croître de de 20.1% par an. Le rendement des capitaux propres devrait être 10.8% dans 3 ans.
Informations clés
20.5%
Taux de croissance des bénéfices
20.1%
Taux de croissance du BPA
Medical Equipment croissance des bénéfices | 35.1% |
Taux de croissance des recettes | 16.8% |
Rendement futur des capitaux propres | 10.8% |
Couverture par les analystes | Low |
Dernière mise à jour | 31 Mar 2024 |
Mises à jour récentes de la croissance future
Pas de mise à jour
Recent updates
Some Confidence Is Lacking In LifeTech Scientific Corporation's (HKG:1302) P/E
Jul 05LifeTech Scientific's (HKG:1302) Soft Earnings Are Actually Better Than They Appear
Apr 25What LifeTech Scientific Corporation's (HKG:1302) P/E Is Not Telling You
Dec 25Returns On Capital At LifeTech Scientific (HKG:1302) Have Stalled
Nov 28At HK$2.37, Is LifeTech Scientific Corporation (HKG:1302) Worth Looking At Closely?
Nov 03Investors Met With Slowing Returns on Capital At LifeTech Scientific (HKG:1302)
Aug 17Is There Now An Opportunity In LifeTech Scientific Corporation (HKG:1302)?
Jul 18Investors Met With Slowing Returns on Capital At LifeTech Scientific (HKG:1302)
May 05Here's What To Make Of LifeTech Scientific's (HKG:1302) Decelerating Rates Of Return
Oct 14There's Been No Shortage Of Growth Recently For LifeTech Scientific's (HKG:1302) Returns On Capital
Jul 15Does LifeTech Scientific (HKG:1302) Deserve A Spot On Your Watchlist?
Jun 30A Look At The Fair Value Of LifeTech Scientific Corporation (HKG:1302)
Jun 15Returns At LifeTech Scientific (HKG:1302) Are On The Way Up
Apr 03Here's Why I Think LifeTech Scientific (HKG:1302) Is An Interesting Stock
Mar 15Is LifeTech Scientific Corporation (HKG:1302) Potentially Undervalued?
Jan 22Some Investors May Be Worried About LifeTech Scientific's (HKG:1302) Returns On Capital
Dec 19Here's Why I Think LifeTech Scientific (HKG:1302) Might Deserve Your Attention Today
Dec 06Is LifeTech Scientific (HKG:1302) A Risky Investment?
Nov 20An Intrinsic Calculation For LifeTech Scientific Corporation (HKG:1302) Suggests It's 34% Undervalued
Oct 12The Returns On Capital At LifeTech Scientific (HKG:1302) Don't Inspire Confidence
Sep 13Should You Be Adding LifeTech Scientific (HKG:1302) To Your Watchlist Today?
Aug 28What Is LifeTech Scientific Corporation's (HKG:1302) Share Price Doing?
Aug 13LifeTech Scientific's (HKG:1302) Returns On Capital Not Reflecting Well On The Business
Jun 08Here's Why I Think LifeTech Scientific (HKG:1302) Is An Interesting Stock
May 26Should You Investigate LifeTech Scientific Corporation (HKG:1302) At HK$4.14?
May 11LifeTech Scientific (HKG:1302) Could Easily Take On More Debt
Mar 31Shareholders Are Thrilled That The LifeTech Scientific (HKG:1302) Share Price Increased 274%
Feb 21Do Insiders Own Lots Of Shares In LifeTech Scientific Corporation (HKG:1302)?
Jan 26Does LifeTech Scientific's (HKG:1302) Statutory Profit Adequately Reflect Its Underlying Profit?
Dec 13Are Strong Financial Prospects The Force That Is Driving The Momentum In LifeTech Scientific Corporation's HKG:1302) Stock?
Nov 25Prévisions de croissance des bénéfices et des revenus
Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
---|---|---|---|---|---|
12/31/2025 | 1,774 | 399 | N/A | 406 | 1 |
12/31/2024 | 1,474 | 328 | N/A | 325 | 1 |
12/31/2023 | 1,267 | 263 | 125 | 418 | N/A |
9/30/2023 | 1,224 | 297 | 84 | 393 | N/A |
6/30/2023 | 1,182 | 331 | 43 | 367 | N/A |
3/31/2023 | 1,139 | 328 | 48 | 378 | N/A |
12/31/2022 | 1,097 | 325 | 53 | 388 | N/A |
9/30/2022 | 1,058 | 314 | 86 | 437 | N/A |
6/30/2022 | 1,019 | 303 | 119 | 486 | N/A |
3/31/2022 | 972 | 298 | 108 | 464 | N/A |
12/31/2021 | 925 | 292 | 98 | 441 | N/A |
9/30/2021 | 878 | 307 | 147 | 436 | N/A |
6/30/2021 | 830 | 322 | 196 | 432 | N/A |
3/31/2021 | 736 | 269 | 188 | 385 | N/A |
12/31/2020 | 642 | 216 | 180 | 339 | N/A |
9/30/2020 | 638 | 176 | 154 | 303 | N/A |
6/30/2020 | 633 | 136 | 128 | 268 | N/A |
3/31/2020 | 651 | 132 | 144 | 271 | N/A |
12/31/2019 | 669 | 129 | 161 | 275 | N/A |
9/30/2019 | 644 | 138 | 146 | 252 | N/A |
6/30/2019 | 618 | 146 | 132 | 229 | N/A |
3/31/2019 | 588 | 134 | 101 | 206 | N/A |
12/31/2018 | 557 | 121 | 70 | 182 | N/A |
9/30/2018 | 518 | 134 | 71 | 190 | N/A |
6/30/2018 | 480 | 147 | 72 | 199 | N/A |
3/31/2018 | 445 | 155 | 37 | 177 | N/A |
12/31/2017 | 409 | 163 | 2 | 155 | N/A |
9/30/2017 | 391 | 171 | N/A | 146 | N/A |
6/30/2017 | 373 | 178 | N/A | 136 | N/A |
3/31/2017 | 363 | 162 | N/A | 132 | N/A |
12/31/2016 | 353 | 146 | N/A | 127 | N/A |
9/30/2016 | 336 | 201 | N/A | 121 | N/A |
6/30/2016 | 319 | 256 | N/A | 115 | N/A |
3/31/2016 | 315 | 129 | N/A | 130 | N/A |
12/31/2015 | 312 | 2 | N/A | 144 | N/A |
9/30/2015 | 304 | -41 | N/A | 113 | N/A |
6/30/2015 | 296 | -84 | N/A | 81 | N/A |
3/31/2015 | 289 | -83 | N/A | 50 | N/A |
12/31/2014 | 283 | -81 | N/A | 20 | N/A |
9/30/2014 | 280 | -151 | N/A | N/A | N/A |
6/30/2014 | 258 | -209 | N/A | 6 | N/A |
3/31/2014 | 248 | -89 | N/A | N/A | N/A |
12/31/2013 | 231 | -66 | N/A | 35 | N/A |
9/30/2013 | 209 | -53 | N/A | N/A | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de 1302 ( 20.5% par an) est supérieure au taux d'épargne ( 2.3% ).
Bénéfices vs marché: Les bénéfices de 1302 ( 20.5% par an) devraient croître plus rapidement que le marché Hong Kong ( 11% par an).
Croissance élevée des bénéfices: Les bénéfices de 1302 devraient augmenter de manière significative au cours des 3 prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de 1302 ( 16.8% par an) devrait croître plus rapidement que le marché Hong Kong ( 7.4% par an).
Croissance élevée des revenus: Le chiffre d'affaires de 1302 ( 16.8% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Le retour sur capitaux propres de 1302 devrait être faible dans 3 ans ( 10.8 %).